Navigation Links
Jubilant and BioLeap Announce New Partnership in Drug Discovery

NOIDA, India and NEW HOPE, Pa., Jan. 13 /PRNewswire/ -- Jubilant Organosys Ltd., headquartered at Noida, near New Delhi, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a drug discovery partnership with BioLeap, LLC, USA. Under this partnership, BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform. The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to IND (Investigational New Drug) candidate selection for multiple therapeutic areas.

Commenting on the development, Sri Mosur, CEO & President, Jubilant Biosys, said: "We are very pleased to partner with BioLeap to offer the pharmaceutical industry our combined 'best in class' preclinical drug discovery capabilities."

Gerald Evans, BioLeap Chief Business Officer added, "We are delighted to have the opportunity to offer our partners the combined capabilities of Jubilant and BioLeap. This partnership leverages and combines the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development with BioLeap's leading edge computational fragment-based design capabilities, to deliver high quality, cost-effective pre-clinical drug discovery services."

BioLeap's platform technology is completely "in-silico," and it quickly predicts binding information providing drug designers new insights to efficiently create novel molecules and/or improve existing molecules without the limitations of library screening, thereby reducing the time and cost of traditional screening methods.

Many current screening programs have hit barriers with regards to finding small molecule candidates for viable validated targets because of limitations in chemical diversity. BioLeap's technology provides a viable solution to this current paradigm. The combined strengths of JBL/BioLeap partnership would be most attractive to companies engaged in rational drug design in therapeutic areas where Structural Biology plays a key role, which includes but is not limited to any of the top twenty pharmaceutical companies working on anti-infectives, oncology, CNS and other therapeutic areas.

About Jubilant Biosys

Jubilant Biosys Ltd. ( is a subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery and development solutions to the global pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys Center in Bangalore integrates the capabilities of over 300 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modeling, crystallography and information technology to support collaborations with global pharma companies in USA, Europe and Japan.

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and Health Care. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.

About BioLeap

BioLeap is a leader in computational fragment-based drug design. The company's proprietary design technology and process successfully addresses one of the biggest problems in pre-clinical drug discovery: the limitation of druggable and patentable leads for important biological targets. BioLeap is using its capabilities to advance its internal programs and has also entered into numerous drug design collaborations with pharmaceutical partners.

Further information about Jubilant Organosys is available at and about BioLeap at

SOURCE Jubilant Organosys Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 According to two new ... 2005. This is something that many doctors, scientists, and public ... questions remains: with fewer PSA tests being done, will there ... Dr. David Samadi, "Despite the efforts made ... remains the second leading cancer cause of death in men, ...
(Date:11/23/2015)... China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing, and stem ... results for the second quarter and first half of ... --> --> Second Quarter of ... quarter of fiscal 2016 increased by 12.7% to RMB171.5 ...
(Date:11/23/2015)... The royalty-free a greement ... develop daclatasvir for 112 low- and m ... --> --> The Medicines Patent Pool (MPP) ... signing an agreement with Bristol-Myers Squibb for daclatasvir, a novel ... of the HCV virus.  The royalty-free licence will enable generic ...
(Date:11/23/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading medical ... surgery, announced today that it will participate in the upcoming ... December 2, 2015 at The New York Palace Hotel in ... Mackin , President and Chief Executive Officer. --> ... --> A live webcast of the Company,s presentation ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):